Home · Reading room · Two prescriptions
Two prescriptionsOn endometriosis hormone therapy and considering a GLP-1? The conversation to have first
Two clinicians, two prescriptions, and one body in the middle. Here is how to make sure they are talking about the same person.
Hormonal medication is one of the most common ways endometriosis is managed. For many people that means a pill: a combined contraceptive taken continuously, a progestin-only medication, or one of the newer oral treatments your gynecologist may have prescribed. If you are now considering a GLP-1 for weight or metabolic health, those two prescriptions need to be discussed together before your first dose, not after.
This is not a reason for alarm. It is a reason for a specific, short conversation, and knowing what to raise makes that conversation easy.
What the tirzepatide label says
Tirzepatide, the medication most telehealth GLP-1 programs prescribe, slows how quickly the stomach empties. That can reduce how much of an oral medication is absorbed, especially in the weeks after starting and after each dose increase, when the effect is strongest.
For that reason, the FDA label for tirzepatide (Zepbound and Mounjaro) advises that anyone using an oral hormonal contraceptive switch to a non-oral method, or add a barrier method, for four weeks after starting and for four weeks after each dose increase. Hormonal methods that are not taken by mouth, such as an IUD, implant, patch, ring or injection, are not expected to be affected in the same way.
The label speaks to contraception. If your oral hormonal medication is there to manage endometriosis rather than, or as well as, to prevent pregnancy, the same absorption question is worth putting to the clinician who prescribed it: does a period of reduced absorption matter for my symptom control, and what should I do about it?
What to tell your GLP-1 provider
- Every hormonal medication you take for endometriosis, by name, dose and how you take it.
- Whether it is doing contraceptive work for you as well as symptom work.
- Who prescribes it, so the two of them can coordinate if needed.
- Whether you are trying to conceive or might become pregnant. GLP-1 medications are not used in pregnancy, and the labels advise stopping when pregnancy is recognised; semaglutide’s label advises stopping at least two months before a planned pregnancy.
A good provider will ask about all four without prompting. If they do not, you have learned something useful about the program.
What to ask your gynecologist or specialist
- “If my oral medication is absorbed less for a few weeks, what might I notice, and does it matter for my endo?”
- “Would a non-oral option make sense for me, now or while my dose is changing?”
- “What should I report to you if my symptoms change after I start?”
Take the answers back to your GLP-1 provider. You are the only person who sees both prescriptions every day, and a sentence from each clinician to the other can save weeks of guessing.
The medication is not the risk here. Two clinicians who never hear about each other are.
Why this sits inside the Charter
This conversation is the first promise of the Whole-Woman Charter, reading your whole history, and the fourth, a dose titrated to how you respond. A provider who plans dose increases around your hormonal medication, rather than on a fixed calendar, is doing both at once. If you are still choosing a provider, our appointment script covers how to open this topic in the first five minutes.